Alpha 2.0
Login Register
» Authors » Chenxiong Le

Chenxiong Le

Explore the profile of Chenxiong Le including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 9
Citations 358
Followers 0
Related Specialties
Gastroenterology
Rheumatology
Public Health
Top 10 Co-Authors
Wendy I White
Barbara White
Yihong Yao
Bahija Jallal
John F Kokai-Kun
Klaus Gottlieb
Tyler Porter
Christine Cruz
Laura Richman
Gabriel Robbie
Published In
Ann Rheum Dis
Gastroenterol Rep (Oxf)
Stat Med
Infect Drug Resist
J Am Acad Dermatol
Affiliations
Soon will be listed here.
Recent Articles
1.
Ribaxamase, an Orally Administered β-Lactamase, Diminishes Changes to Acquired Antimicrobial Resistance of the Gut Resistome in Patients Treated with Ceftriaxone
Kokai-Kun J, Le C, Trout K, Cope J, Ajami N, Degar A, et al.
Infect Drug Resist . 2020 Aug; 13:2521-2535. PMID: 32801790
Introduction: Intravenous (IV) β-lactam antibiotics, excreted through bile into the gastrointestinal (GI) tract, may disrupt the gut microbiome by eliminating the colonization resistance from beneficial bacteria. This increases the risk...
2.
Use of ribaxamase (SYN-004), a β-lactamase, to prevent Clostridium difficile infection in β-lactam-treated patients: a double-blind, phase 2b, randomised placebo-controlled trial
Kokai-Kun J, Roberts T, Coughlin O, Le C, Whalen H, Stevenson R, et al.
Lancet Infect Dis . 2019 Mar; 19(5):487-496. PMID: 30885591
Background: Infections with Clostridium difficile are a health threat, yet no products are currently licensed for prevention of primary C difficile infections. Intravenous β-lactam antibiotics are considered to confer a...
3.
Erratum: Selection of a cut-off for high- and low-methane producers using a spot-methane breath test: results from a large north American dataset of hydrogen, methane and carbon dioxide measurements in breath
Gottlieb K, Le C, Wacher V, Sliman J, Cruz C, Porter T, et al.
Gastroenterol Rep (Oxf) . 2018 Aug; 6(3):242. PMID: 30151210
[This corrects the article DOI: 10.1093/gastro/gow048.][This corrects the article DOI: 10.1093/gastro/gow048.].
4.
Selection of a cut-off for high- and low-methane producers using a spot-methane breath test: results from a large north American dataset of hydrogen, methane and carbon dioxide measurements in breath
Gottlieb K, Le C, Wacher V, Sliman J, Cruz C, Porter T, et al.
Gastroenterol Rep (Oxf) . 2017 Jan; 5(3):193-199. PMID: 28130375
Background: Levels of breath methane, together with breath hydrogen, are determined by means of repeated collections of both, following ingestion of a carbohydrate substrate, at 15-20 minutes intervals, until 10...
5.
A phase 1b clinical trial evaluating sifalimumab, an anti-IFN-α monoclonal antibody, shows target neutralisation of a type I IFN signature in blood of dermatomyositis and polymyositis patients
Higgs B, Zhu W, Morehouse C, White W, Brohawn P, Guo X, et al.
Ann Rheum Dis . 2013 Feb; 73(1):256-62. PMID: 23434567
Objective: To assess the pharmacodynamic effects of sifalimumab, an investigational anti-IFN-α monoclonal antibody, in the blood and muscle of adult dermatomyositis and polymyositis patients by measuring neutralisation of a type...
6.
Safety profile and clinical activity of sifalimumab, a fully human anti-interferon α monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study
Merrill J, Wallace D, Petri M, Kirou K, Yao Y, White W, et al.
Ann Rheum Dis . 2011 Jul; 70(11):1905-13. PMID: 21798883
Background: Type I interferons (IFNs) appear to play a central role in disease pathogenesis in systemic lupus erythematosus (SLE), making them potential therapeutic targets. Methods: Safety profile, pharmacokinetics, immunogenicity, pharmacodynamics...
7.
Safety profile and clinical activity of multiple subcutaneous doses of MEDI-528, a humanized anti-interleukin-9 monoclonal antibody, in two randomized phase 2a studies in subjects with asthma
Parker J, Oh C, LaForce C, Miller S, Pearlman D, Le C, et al.
BMC Pulm Med . 2011 Mar; 11:14. PMID: 21356110
Background: Interleukin-9 (IL-9)-targeted therapies may offer a novel approach for treating asthmatics. Two randomized placebo-controlled studies were conducted to assess the safety profile and potential efficacy of multiple subcutaneous doses...
8.
A randomized, double-blind, placebo-controlled, phase I study of MEDI-545, an anti-interferon-alfa monoclonal antibody, in subjects with chronic psoriasis
Bissonnette R, Papp K, Maari C, Yao Y, Robbie G, White W, et al.
J Am Acad Dermatol . 2010 Feb; 62(3):427-36. PMID: 20159310
Background: Interferon-alfa (IFN-alpha) has been implicated in the pathogenesis of psoriasis. Objective: To evaluate the safety profile of MEDI-545, a fully human anti-IFN-alpha monoclonal antibody and to explore its effect...
9.
Age-conditional probabilities of developing cancer
Fay M, Pfeiffer R, Cronin K, Le C, Feuer E
Stat Med . 2003 May; 22(11):1837-48. PMID: 12754719
We propose an estimator of the probability of developing a disease in a given age range, conditional on never having developed the disease prior to the beginning of the age...